A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

Castration Resistant ◽

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-2605 ◽

2012 ◽

Vol 19 (1) ◽

pp. 215-224 ◽

Cited By ~ 58

Author(s):

Charles J. Ryan ◽

Mark Rosenthal ◽

Siobhan Ng ◽

Joshi Alumkal ◽

Joel Picus ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Biomarker Analysis

A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4532 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4532-4532 ◽

Cited By ~ 4

Author(s):

E. S. Antonarakis ◽

E. I. Heath ◽

D. C. Smith ◽

D. E. Rathkopf ◽

A. L. Blackford ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Dose Levels

A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5081 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5081-5081 ◽

Cited By ~ 1

Author(s):

Joyce M. van Dodewaard-de Jong ◽

Haiko Bloemendal ◽

John M. H. de Klerk ◽

Daniela E Oprea-Lager ◽

Otto S. Hoekstra ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71382-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 407 ◽

Cited By ~ 2

Author(s):

K.N. Chi ◽

S.J. Hotte ◽

E. Yu ◽

D. Tu ◽

B. Eigl ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

Anti-Cancer Drugs ◽

10.1097/cad.0000000000000131 ◽

2014 ◽

Vol 25 (9) ◽

pp. 1081-1088 ◽

Cited By ~ 8

Author(s):

Jean-Pierre Droz ◽

Jaques Medioni ◽

Christine Chevreau ◽

Helene De Mont-Serrat ◽

Michael Merger ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5017 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5017-5017 ◽

Cited By ~ 8

Author(s):

Johann S. De Bono ◽

Ugo De Giorgi ◽

Christophe Massard ◽

Sergio Bracarda ◽

Ivo Kocak ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Docetaxel Chemotherapy

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

Annals of Oncology ◽

10.1093/annonc/mdn784 ◽

2009 ◽

Vol 20 (7) ◽

pp. 1264-1269 ◽

Cited By ~ 79

Author(s):

C.N. Sternberg ◽

H. Dumez ◽

H. Van Poppel ◽

I. Skoneczna ◽

A. Sella ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Antisense Oligonucleotide ◽

Phase Ii Study ◽

Castration Resistant ◽

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

Cancer Medicine ◽

10.1002/cam4.3806 ◽

2021 ◽

Author(s):

Judith Passildas‐Jahanmohan ◽

Jean‐Christophe Eymard ◽

Mélanie Pouget ◽

Fabrice Kwiatkowski ◽

Isabelle Van Praagh ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Castration Resistant ◽

Randomized Phase Ii ◽

First Line Treatment

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

Investigational New Drugs ◽

10.1007/s10637-014-0106-5 ◽

2014 ◽

Vol 32 (5) ◽

pp. 1005-1016 ◽

Cited By ~ 18

Author(s):

Anna Spreafico ◽

Kim N. Chi ◽

Srikala S. Sridhar ◽

David C. Smith ◽

Michael A. Carducci ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study

Cytotherapy ◽

10.1016/j.jcyt.2017.01.007 ◽

2017 ◽

Vol 19 (4) ◽

pp. 500-513 ◽

Cited By ~ 24

Author(s):

Per Kongsted ◽

Troels Holz Borch ◽

Eva Ellebaek ◽

Trine Zeeberg Iversen ◽

Rikke Andersen ◽

...

Keyword(s):

Prostate Cancer ◽

Dendritic Cell ◽

Phase Ii ◽

Phase Ii Study ◽

Dendritic Cell Vaccination ◽

Castration Resistant ◽